FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064381694> ?p ?o ?g. }

• W2064381694 endingPage "418" @default.
• W2064381694 startingPage "418" @default.
• W2064381694 abstract "Mitoxantrone is an approved disease modifying agent for treatment of multiple sclerosis (MS). The aim of the study was to assess its efficacy and safety in Indian MS patients.A total of 23 patients with clinically definite MS (Poser criteria) were enrolled in an open label study. Of which, 21 satisfied the McDonald's criteria for MS and two satisfied the diagnostic criteria of neuromyelitis optica (NMO). The numbers of relapses and expanded disability status scale (EDSS) score were used as primary and secondary outcome measures. The patients were monitored for the adverse effects.In 17 (15 MS and two NMO) patients who completed one year of therapy, there was significant difference in the mean annual relapse rates [before 0.879+/-0.58; on mitoxantrone 0.091+/-0.17, (P=0.003)]. Of the 17 patients, ten (MS 9 and NMO 1) completed therapy for two years. Annual relapse rates [before (1.024+/-0.59), on therapy (0.155+/-0.21), (P=0.0054)] and EDSS score [before start of therapy 5.3, at the end of therapy 2.4, (P=0.001)] showed significant benefit in the ten patients who completed two years therapy. This benefit persisted during the mean follow-up period of two and a half years after completion of therapy. The adverse events noted in the entire cohort were leucopenia in four patients and asymptomatic reversible decrease in cardiac ejection fraction in one patient. Leucopenia was severe in two patients requiring discontinuation of the therapy and mitoxantrone was also discontinued in the patient with cardiotoxicity.Mitoxantrone, as an initial therapy, decreases clinical exacerbations and disability progression, and has a reasonable safety profile in Indian patients with MS and NMO." @default.
• W2064381694 created "2016-06-24" @default.
• W2064381694 creator A5010005544 @default.
• W2064381694 creator A5016032365 @default.
• W2064381694 creator A5030550795 @default.
• W2064381694 creator A5066256080 @default.
• W2064381694 date "2009-01-01" @default.
• W2064381694 modified "2023-09-26" @default.
• W2064381694 title "Efficacy and safety of Mitoxantrone, as an initial therapy, in multiple sclerosis: Experience in an Indian tertiary care setting" @default.
• W2064381694 cites W1970288844 @default.
• W2064381694 cites W1975254445 @default.
• W2064381694 cites W1984026653 @default.
• W2064381694 cites W1998029081 @default.
• W2064381694 cites W2012365353 @default.
• W2064381694 cites W2021379157 @default.
• W2064381694 cites W2025790867 @default.
• W2064381694 cites W2026413027 @default.
• W2064381694 cites W2038610301 @default.
• W2064381694 cites W2051941539 @default.
• W2064381694 cites W2061354173 @default.
• W2064381694 cites W2066919899 @default.
• W2064381694 cites W2078484837 @default.
• W2064381694 cites W2087589796 @default.
• W2064381694 cites W2088950613 @default.
• W2064381694 cites W2099462160 @default.
• W2064381694 cites W2101674248 @default.
• W2064381694 cites W2105490558 @default.
• W2064381694 cites W2110477182 @default.
• W2064381694 cites W2112165124 @default.
• W2064381694 cites W2119077291 @default.
• W2064381694 cites W2119172537 @default.
• W2064381694 cites W2130355701 @default.
• W2064381694 cites W2135298552 @default.
• W2064381694 cites W2136132690 @default.
• W2064381694 cites W2144633544 @default.
• W2064381694 cites W2404076384 @default.
• W2064381694 cites W2916040650 @default.
• W2064381694 cites W2223695946 @default.
• W2064381694 doi "https://doi.org/10.4103/0028-3886.55611" @default.
• W2064381694 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19770542" @default.
• W2064381694 hasPublicationYear "2009" @default.
• W2064381694 type Work @default.
• W2064381694 sameAs 2064381694 @default.
• W2064381694 citedByCount "10" @default.
• W2064381694 countsByYear W20643816942012 @default.
• W2064381694 countsByYear W20643816942013 @default.
• W2064381694 countsByYear W20643816942015 @default.
• W2064381694 countsByYear W20643816942019 @default.
• W2064381694 crossrefType "journal-article" @default.
• W2064381694 hasAuthorship W2064381694A5010005544 @default.
• W2064381694 hasAuthorship W2064381694A5016032365 @default.
• W2064381694 hasAuthorship W2064381694A5030550795 @default.
• W2064381694 hasAuthorship W2064381694A5066256080 @default.
• W2064381694 hasBestOaLocation W20643816942 @default.
• W2064381694 hasConcept C118552586 @default.
• W2064381694 hasConcept C126322002 @default.
• W2064381694 hasConcept C187212893 @default.
• W2064381694 hasConcept C197934379 @default.
• W2064381694 hasConcept C2776694085 @default.
• W2064381694 hasConcept C2777910003 @default.
• W2064381694 hasConcept C2778715236 @default.
• W2064381694 hasConcept C2779134260 @default.
• W2064381694 hasConcept C2780640218 @default.
• W2064381694 hasConcept C2780892749 @default.
• W2064381694 hasConcept C2780923524 @default.
• W2064381694 hasConcept C2781004633 @default.
• W2064381694 hasConcept C2781137167 @default.
• W2064381694 hasConcept C71924100 @default.
• W2064381694 hasConceptScore W2064381694C118552586 @default.
• W2064381694 hasConceptScore W2064381694C126322002 @default.
• W2064381694 hasConceptScore W2064381694C187212893 @default.
• W2064381694 hasConceptScore W2064381694C197934379 @default.
• W2064381694 hasConceptScore W2064381694C2776694085 @default.
• W2064381694 hasConceptScore W2064381694C2777910003 @default.
• W2064381694 hasConceptScore W2064381694C2778715236 @default.
• W2064381694 hasConceptScore W2064381694C2779134260 @default.
• W2064381694 hasConceptScore W2064381694C2780640218 @default.
• W2064381694 hasConceptScore W2064381694C2780892749 @default.
• W2064381694 hasConceptScore W2064381694C2780923524 @default.
• W2064381694 hasConceptScore W2064381694C2781004633 @default.
• W2064381694 hasConceptScore W2064381694C2781137167 @default.
• W2064381694 hasConceptScore W2064381694C71924100 @default.
• W2064381694 hasIssue "4" @default.
• W2064381694 hasLocation W20643816941 @default.
• W2064381694 hasLocation W20643816942 @default.
• W2064381694 hasLocation W20643816943 @default.
• W2064381694 hasLocation W20643816944 @default.
• W2064381694 hasOpenAccess W2064381694 @default.
• W2064381694 hasPrimaryLocation W20643816941 @default.
• W2064381694 hasRelatedWork W1965775453 @default.
• W2064381694 hasRelatedWork W1987289843 @default.
• W2064381694 hasRelatedWork W2016226163 @default.
• W2064381694 hasRelatedWork W2073757924 @default.
• W2064381694 hasRelatedWork W2260535563 @default.
• W2064381694 hasRelatedWork W2522065455 @default.
• W2064381694 hasRelatedWork W2804387447 @default.
• W2064381694 hasRelatedWork W2886874806 @default.
• W2064381694 hasRelatedWork W3182698062 @default.

• next